228413-59-0

Basic information

• Product Name: Ethyl 4-phenyl-2-(pyridin-4-yl)thiazole-5-carboxylate
• Synonyms: Ethyl 4-phenyl-2-(pyridin-4-yl)thiazole-5-carboxylate
• CAS NO: 228413-59-0
• Molecular Formula: C17H14N2O2S
• Molecular Weight: 310.37026
• Mol File: 228413-59-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 4-phenyl-2-(pyridin-4-yl)thiazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-phenyl-2-(pyridin-4-yl)thiazole-5-carboxylate(228413-59-0)
• EPA Substance Registry System: Ethyl 4-phenyl-2-(pyridin-4-yl)thiazole-5-carboxylate(228413-59-0)

Safety Data

• Hazardous Substances Data: 228413-59-0(Hazardous Substances Data)

Upstream product

• 685-87-0 Diethyl 2-bromomalonate 
• 55919-47-6 ethyl 2-bromo-3-oxo-3-phenylpropionate 
• 2196-13-6 pyridine-4-carbothioamide 
• 630409-69-7 ethyl 2-(pyridin-4-yl)-4-[(trifluoromethyl)sulfonyloxy]-1,3-thiazole-5-carboxylate 
• 98-80-6 phenylboronic acid 
• 190271-73-9 ethyl 4-hydroxy-2-(4-pyridyl)-1,3-thiazole-5-carboxylate 

Downstream Products

• 1225963-57-4 4-phenyl-2-(pyridin-4-yl)thiazole-5-carboxylic acid 
• 1612886-74-4 4-phenyl-2-(pyridin-4-yl)thiazole-5-carbohydrazide 
• 1148158-15-9 N-hydroxy-4-phenyl-2-(pyridin-4-yl)thiazole-5-carboxamide 
• 1612886-79-9 2-(4-phenyl-2-(pyridin-4-yl)thiazol-5-yl)-1,3,4-oxadiazole 

Relevant articles and documents

THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors

The Cell division cycle 7 (Cdc7) protein kinase is essential for DNA replication and maintenance of genome stability. We systematically explored thiazole-based compounds as inhibitors of Cdc7 kinase activity in cancer cells. Our studies resulted in the identification of a potent, selective Cdc7 inhibitor that decreased phosphorylation of the direct substrate MCM2 in vitro and in vivo, and inhibited DNA synthesis and cell viability in vitro.

HETEROARYLS AND THEIR USE AS PI3K INHIBITORS

This invention provides compounds of formula (IA) or (IB): wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.